

**Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting
Public Workshop – July 10-11, 2017
Docket No. FDA-2017-N-2903
Center for Drug Evaluation and Research
Food and Drug Administration
Department of Health and Human Services**

List of FDA Participants

Scott Gottlieb, MD
Commissioner
US Food and Drug Administration

Doug C. Throckmorton, MD
Deputy Director for Regulatory Programs
Office of the Center Director
Center for Drug Research & Evaluation
US Food and Drug Administration

Judy A. Staffa, PhD, RPh
Associate Director for Public Health Initiatives
Office of Surveillance & Epidemiology
Center for Drug Research & Evaluation
US Food and Drug Administration

Mark Levenson, PhD
Director
Division of Biometrics VII
Office of Biostatistics
Center for Drug Evaluation and Research
US Food and Drug Administration

Kunthel By, PhD
Division of Biometrics VII
Office of Biostatistics
Center for Drug Research & Evaluation
US Food and Drug Administration

Cynthia Kornegay, PhD
Lead, Prescription Drug Abuse Team
Division of Epidemiology II
Office of Surveillance & Epidemiology
Center for Drug Research & Evaluation
US Food and Drug Administration

Hana Lee, PhD
Division of Biometrics VII
Office of Biostatistics

Center for Drug Research & Evaluation
US Food and Drug Administration

Jana McAninch, MD, MPH, MS
Division of Epidemiology II
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
US Food and Drug Administration

Tamra Meyer, PhD, MPH
Lead Epidemiologist
Division of Epidemiology II
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
US Food and Drug Administration

Diqiong (Joan) Xie, PhD
Division of Biometrics VII
Office of Biostatistics
Center for Drug Evaluation and Research
US Food and Drug Administration